World Sleep Industry ENCYCLOPEDIA

Tianwang Buxin Pills

2.1.2

Finished-product identity and formula boundary

Tianwang Buxin Pills is the name of a registered Chinese patent medicine in WSIC 2.1.2. The current pharmacopoeial concentrated pill and a publicly available large honey-pill label both list sixteen ingredients: Salvia root, Acorus rhizome, Chinese angelica root, Codonopsis root, schisandra fruit, poria, dwarf lilyturf root, asparagus root, rehmannia root, figwort root, prepared polygala root, fried sour jujube seed, arborvitae seed, platycodon root, licorice, and cinnabar. The registered traditional function is to nourish yin and blood and calm the heart, for a traditional pattern described by palpitations, forgetfulness, insomnia with many dreams, and dry stool. That language is not a modern causal diagnosis.

Tianwang Buxin Dan, Tianwang Buxin Wan or Pills, and Tianwang Buxin tablets can appear as distinct entries in reimbursement or product systems. Large honey pills, small honey pills, water pills, concentrated pills, tablets, regional products, and export products may differ in formula, excipients, manufacturing, strength, and regulatory status. Similar names do not establish interchangeability, and pill counts, grams, or “equivalent crude herbs” must not be converted across products by the user. Confirm the exact generic name, dosage form, approval number, authorization holder, and full ingredient panel on the package in hand.

Dosage form, strength, and label priority

One public large honey-pill product is labeled as nine grams per pill and for use under a physician's guidance, whereas the pharmacopoeial concentrated pill is specified as eight pills equivalent to three grams of crude herbal slices. The units, production pathways, and labeled directions are different. These figures illustrate why instructions cannot be copied from one product to another; they are not individualized dosing advice. Use the current physical package insert and the prescriber's directions, not an old web page, retail listing, or a different bottle kept at home.

Revisions and product-specific differences also affect warnings. The pharmacopoeial concentrated-pill entry lists an acute cerebral hemorrhage contraindication and dietary cautions, while the cited large honey-pill label emphasizes that it contains cinnabar, should not be overused or taken for a prolonged period, warrants caution in hepatic or renal impairment, and requires removal of the wax or plastic shell before use. Follow every contraindication, duration limit, administration instruction, storage condition, and packaging direction on the actual product. An omitted warning does not prove absence of risk.

Traditional claims and assessment of insomnia

“Heart-yin deficiency” and “calming the heart” are traditional pattern and function terms. A single poor night, palpitations, or perceived memory decline is not enough to select this medicine. Difficulty falling asleep, night waking, early waking, and daytime impairment may instead reflect inadequate sleep opportunity, circadian misalignment, anxiety or depression, pain, thyroid or cardiovascular disease, caffeine, alcohol, or medicines. Palpitations and constipation also require cause-based assessment rather than substitution with a traditional symptom label.

Loud snoring, witnessed pauses in breathing, nocturnal choking, morning headache, restless-legs symptoms, unusual sleep behaviors, a short period of marked activation or reduced need for sleep, progressive cognitive change, and thoughts of self-harm require appropriate evaluation. Persistent palpitations or those accompanied by chest pain, fainting, or breathlessness must not be managed with this product alone. Tianwang Buxin Pills does not replace electrocardiographic evaluation, sleep-apnea testing, psychiatric emergency care, or treatment directed at an identified cause.

Human evidence and its limitations

A systematic review of insomnia included fourteen studies with 1,256 participants. Pooled results suggested that Tian Wang Bu Xin Dan alone or added to conventional medicine might improve some subjective outcomes. Most trials, however, inadequately described random-sequence generation, allocation concealment, and blinding; none used a placebo, formulations and outcomes varied, and only five trials reported adverse events. The signal supports further research but does not establish long-term effectiveness or safety, equivalence to standard care, or superiority.

The review title and included interventions centered on Tian Wang Bu Xin Dan. Modified decoctions, combination therapy, and different finished products in those studies do not automatically represent the bottle of Tianwang Buxin Pills being considered. Sedative experiments in animals and studies of one herb or constituent likewise cannot establish a net clinical benefit for the finished product. Interpretation must match the exact formula, dosage form, authorization holder, batch, duration, comparator, and outcome, and must distinguish questionnaires or sleep diaries from objective sleep architecture.

Cinnabar and mercury-exposure boundary

When cinnabar appears on the ingredient panel, the product entails exposure to mercuric sulfide. Mercuric sulfide is poorly soluble and generally less absorbed by mouth than mercuric chloride or methylmercury, so the toxicity of different mercury species should not be treated as identical. Lower absorption, however, is not zero risk. Dose, duration, processing, heating, co-exposures, and liver and kidney function matter; prolonged or excessive use can increase the possibility of mercury accumulation and renal or neurologic injury.

Do not increase the dose or duration of a cinnabar-containing product, heat or decoct its powder, burn or fumigate it, or repurpose it. Do not stack it with other traditional medicines containing cinnabar, mercury, or undisclosed ingredients. People with hepatic or renal impairment must follow the caution on their label; pregnancy, breastfeeding, childhood, older age, and multiple chronic illnesses require professional review rather than self-treatment. If a particular ingredient panel does not list cinnabar, that still does not make its formulation, dose, or evidence interchangeable with a cinnabar-containing version.

Interactions, adverse signals, and quality

This is a multi-ingredient medicine. Combining it with other sedating patent medicines, hypnotics, anxiolytics, antidepressants, antiseizure medicines, alcohol, or sedating antihistamines may increase drowsiness, dizziness, and falls. Anyone taking multiple medicines, anticoagulants, or narrow-therapeutic-index drugs should have a clinician or pharmacist review the complete list. Separating administration times does not reliably prevent pharmacodynamic or metabolic interactions, and “natural” origin is not a reason to omit the product from medication history.

Stop use and seek care according to severity for rash, swelling of the face, lips, or tongue, breathing difficulty, persistent gastrointestinal symptoms, unusual somnolence, tremor, altered sensation, marked weakness, behavioral or memory change, or changes in urine volume or appearance. Severe acute symptoms need urgent care, with the package brought for identification. Do not induce vomiting or take unverified “mercury detox” products or chelators. Check the approval number, batch, expiry, seal, and storage history; do not use a product with unexplained discoloration, odor, mold, damage, or uncertain origin.

Time-limited use, reassessment, and long-term care

After a professional has confirmed the exact product and its suitability, use should have a defined time boundary set by its label or prescription. Do not add extra doses after a poor night or repeatedly renew it without review. A record of administration time, lights-out time, estimated sleep onset, awakenings, rising time, daytime function, adverse effects, and all medicines and supplements makes reassessment more informative. Lack of improvement by the specified review point, repeated relapse on stopping, or new cardiac, neurologic, or renal symptoms calls for renewed evaluation rather than another self-directed cycle.

Multicomponent cognitive behavioral therapy for insomnia is first-line treatment for chronic insomnia in adults; sleep-hygiene advice alone is not a substitute for the full treatment. Suspected obstructive sleep apnea should be evaluated with polysomnography or an appropriate home sleep apnea test according to the clinical situation. Tianwang Buxin Pills should not be claimed to cure insomnia, increase deep or rapid-eye-movement sleep, enhance memory in healthy people, treat anxiety, depression, arrhythmia, or sleep apnea, or replace an effective treatment selected after proper assessment.